Keywords: eli, lilly/amylin, exenatide, shows, promise, type, diabetes

Eli Lilly/Amylin's exenatide shows promise as type 2 diabetes therapy

Article | 13 September 2004

Print This

At a press briefing at the annual meeting of the European Associationfor the Study of Diabetes, held in Munich, Germany, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in